AzPA Pharmacy Flash

• FDA Approves Neffy 1 MG Nasal Spray for Pediatric Patients
  The FDA has approved ARS Pharmaceuticals' neffy 1mg for treating Type 1 allergic reactions in pediatric patients aged four and above. Neffy is the first significant innovation for this population in over 35 years, addressing the concern of 56% of caregivers about injecting their child.
• AI Augments Pharmacist Intelligence
  Artificial intelligence is increasingly being integrated into clinical decision support systems in ICUs, aiding in decisions like dose optimization and enteral nutrition timing. AI is also being used in tele-critical care settings, where bedside pharmacists are unavailable, such as in rural hospitals.
• Ryoncil, the First FDA-Approved Mesenchymal Stromal Cell Therapy
  Ryoncil, an allogeneic MSC therapy, is used to treat acute graft-versus-host disease in children, a common complication of alloHCT, with a high mortality rate and a need for a novel therapy.